Benzinga | Jun 28, 2021 07:34AM EDT

Roth Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $110

Roth Capital analyst Tony Butler maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $80 to $110.